Achieve Life Sciences Inc
NASDAQ:ACHV

Watchlist Manager
Achieve Life Sciences Inc Logo
Achieve Life Sciences Inc
NASDAQ:ACHV
Watchlist
Price: 3.77 USD -1.31%
Market Cap: 129.5m USD
Have any thoughts about
Achieve Life Sciences Inc?
Write Note

Achieve Life Sciences Inc
Total Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Achieve Life Sciences Inc
Total Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Assets CAGR 3Y CAGR 5Y CAGR 10Y
Achieve Life Sciences Inc
NASDAQ:ACHV
Total Assets
$47.9m
CAGR 3-Years
8%
CAGR 5-Years
33%
CAGR 10-Years
-3%
Abbvie Inc
NYSE:ABBV
Total Assets
$143.4B
CAGR 3-Years
-1%
CAGR 5-Years
19%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Total Assets
$54.5B
CAGR 3-Years
-7%
CAGR 5-Years
-2%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Total Assets
$90.9B
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Assets
$22.2B
CAGR 3-Years
21%
CAGR 5-Years
24%
CAGR 10-Years
25%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Assets
$37.4B
CAGR 3-Years
17%
CAGR 5-Years
22%
CAGR 10-Years
26%
No Stocks Found

Achieve Life Sciences Inc
Glance View

Market Cap
129.7m USD
Industry
Biotechnology

Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. The company is headquartered in Seattle, Washington and currently employs 16 full-time employees. The firm is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring plant-based alkaloid from the seeds of the Laburnum anagyroides plant. Cytisinicline is structurally similar to nicotine and a mechanism of action that is both agonistic and antagonistic. The firm is aid in smoking cessation, or nicotine addiction, by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms through agonistic effects on nicotine receptors and by reducing the reward and satisfaction associated with nicotine through antagonistic properties. The Company’s has two prescription oral treatments for smoking cessation are available in the United States: Chantix (varenicline) and Zyban (bupropion).

ACHV Intrinsic Value
5.1 USD
Undervaluation 26%
Intrinsic Value
Price

See Also

What is Achieve Life Sciences Inc's Total Assets?
Total Assets
47.9m USD

Based on the financial report for Sep 30, 2024, Achieve Life Sciences Inc's Total Assets amounts to 47.9m USD.

What is Achieve Life Sciences Inc's Total Assets growth rate?
Total Assets CAGR 10Y
-3%

Over the last year, the Total Assets growth was 97%. The average annual Total Assets growth rates for Achieve Life Sciences Inc have been 8% over the past three years , 33% over the past five years , and -3% over the past ten years .

Back to Top